Alcon Inc Stock Price, News & Analysis

Alcon (SIX/NYSE: ALC) held its 2025 Annual General Meeting where shareholders approved all proposed resolutions. 332,704,408 shares were represented at the meeting. Key approvals included: the re-election of F. Michael Ball as Board Chair and other existing board members, election of Deborah Di Sanzo as a new board member effective September 1, 2025, and re-election of Compensation Committee members. Shareholders approved a gross dividend of CHF 0.28 per share and granted discharge to Board and Executive Committee members for 2024. The meeting also saw approval of compensation packages for the Board and Executive Committee, along with acceptance of the 2024 Report on Non-Financial Matters and Compensation Report. PricewaterhouseCoopers SA was re-elected as statutory auditors.

Alcon has launched the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS), introducing breakthrough technologies for eye surgery. The platform features HYPERVIT 30K, the world's fastest vitrectomy probe at 30,000 cuts per minute, and UNITY 4D Phaco technology that delivers up to 2X faster nucleus removal with 41% less energy impact.

Key innovations include the UNITY Intelligent Fluidics system, UNITY 27 Gauge Portfolio with Dynamic Stiffener technology, and UNITY TetraSpot illuminated laser probe that reduces laser application time by up to three times. The system also features UNITY Intelligent Sentry, reducing post-occlusion surge volumes by 44%.

The product will begin shipping to Australia, Europe, Japan, and the U.S. from May onwards, with other markets following in Q3 2025 pending regulatory approvals.

Alcon (SIX/NYSE: ALC) has announced its upcoming Annual General Meeting (AGM) scheduled for May 6, 2025. The company proposes to elect Deborah Di Sanzo as a new Board member, bringing her extensive experience in digital, AI, and healthcare technology. Board member Raquel C. Bono, M.D., will not seek re-election after three years of service.

Key agenda items include the proposed cash dividend of CHF 0.28 per share, with an expected ex-dividend date of May 13, 2025 (SIX SIS shares) and May 14, 2025 (DTC shares). The agenda also covers the re-election of current board members, including F. Michael Ball as Chair, and votes on compensation for the Board and Executive Committee.

Alcon (NYSE: ALC) has announced the introduction of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in the U.S. The new IOL features proprietary ENLIGHTEN® NXT Optical technology, delivering 94% light utilization - the highest reported among trifocal IOLs - and half the light scatter compared to its predecessor.

Key improvements include more uninterrupted light distribution and a 16% increase in optical image contrast between distance and intermediate vision. The device will be commercially available in the U.S. in May 2025, featuring powers from +6.0 to +34.0 diopters. It will be the first presbyopia-correcting IOL available in the U.S. from Alcon in the single-use Clareon AutonoMe® preloaded delivery system.

Alcon (ALC) has acquired a majority stake in Aurion Biotech, a clinical-stage company developing advanced cell therapies for eye diseases. The key asset, AURN001, has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy Designations from the FDA for treating corneal edema.

Aurion will operate independently with Alcon's support to advance AURN001 into Phase 3 trials in the second half of 2025. The therapy can produce up to 1,000 doses from a single donor, addressing the global shortage of corneal tissue. Aurion has completed a Phase 1/2 clinical study (CLARA trial) with 97 subjects across the US and Canada.

The company has already achieved its first global commercial launch with Vyznova™ in Japan for treating bullous keratopathy. Dr. Arnaud Lacoste, formerly Chief Scientific Officer, has been appointed as Aurion's CEO.

Alcon (ALC) has received CE Mark approval for Clareon Vivity, an extended depth of focus (EDOF) intraocular lens (IOL) for cataract surgery. The commercial rollout in Europe will begin in early Q2 2025, with the AutonoMe automated pre-loaded delivery system available in Q3 2025.

The Clareon Vivity IOL combines Alcon's advanced Clareon material with Vivity's X-WAVE Technology, providing extended vision range from distance to functional near with minimal visual disturbances. Clinical outcomes show over 90% patient satisfaction rates, including successful results in patients with mild comorbidities such as AMD, glaucoma, and dry eye.

Key features include:

• One of the lowest levels of haze and glistenings compared to competitors
• STABLEFORCE Haptics for excellent axial and rotational stability
• Available in both UV-absorbing and blue light filtering options
• Reduced spectacle dependence while maintaining mesopic contrast sensitivity

Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR), strengthening its cataract equipment portfolio. The acquisition includes LENSAR's ALLY Robotic Cataract Laser System, Streamline software, and legacy laser system.

The deal values LENSAR at $14.00 per share in cash (approximately $356 million), with an additional contingent value right of up to $2.75 per share based on achieving 614,000 cumulative procedures between 2026-2027. The total potential consideration of $16.75 per share represents a 24% premium to LENSAR's 30-day VWAP and 47% to 90-day VWAP, potentially reaching $430 million.

The acquisition targets the growing cataract surgery market, with over 5 million procedures in the U.S. and 32 million globally. The transaction is expected to close in mid-to-late 2025, subject to regulatory approval and LENSAR stockholder approval.

Alcon (SIX/NYSE: ALC), the global leader in eye care, has announced its upcoming 2025 Capital Markets Day, scheduled for March 27, 2025. The event will commence at 8:00 a.m. CT and will be accessible via live webcast through the company's investor relations website.

Interested participants are advised to register and log in approximately 10 minutes prior to the webcast's start time to ensure smooth access to the presentation.

Alcon (ALC) has expanded the parameters of its TOTAL30 for Astigmatism contact lenses, now including a -2.75D cylinder offering. This monthly replacement Water Gradient toric contact lens, the first and only of its kind, maintains a 95% fit success rate and features PRECISION BALANCE 8|4 technology.

The expansion addresses the needs of astigmatic patients, who represent 47% of the patient population and are more prone to dryness and discomfort. The product includes Class 1 UV blocking against UVA and UVB rays and Blue-Violet Light filtration. The expanded parameters now cover 99% of astigmatic patients with a -3.00D cylinder or lower.

This development aligns with Canadian market preferences, where 61% of contact lens wearers choose reusable lenses. The product is now available across Canada, offering stability and month-long comfort at an affordable price.